The aim of this study was to examine the prevalence and clinicopathological significance of KRAS point mutation in endometrial hyperplasia and carcinoma. We analysed KRAS in 11 cases of complex atypical hyperplasia and in 49 endometrial carcinomas using polymerase chain reaction associated with restriction fragment length polymorphism (PCR-RFPL). Point mutations at codon 12 of KRAS oncogene were identified in 7 of 49 (14.3%) tumor specimens and in 2 of 11 (18.2%) hyperplasias. No correlation was found between KRAS gene mutation and age at onset, histology, grade of differentiation and clinical stage. We conclude that KRAS mutation is a relatively common event in endometrial carcinogenesis, but with no prognostic value.
Introduction
Endometrial cancer (EC) develops in about 142000 women worldwide annually being the reason of death in about 42000 women. The most common lesions are typically hormone sensitive and low stage endometrioid cancer which have an excellent prognosis (EC type 1). In contrast, EC type 2 (serous carcinoma) is high grade with a tendency to recur, even at an early stage [1] .
The RAS family G proteins (N-, H-, and KRAS) are thought to play a critical role in the regulation of cellular proliferation. On the other hand evaluation of molecular alterations involved in the regulation of tumor growth, cell death and markers of cancer progression have provided the fundamental basis for the development of molecular targeted therapies [2] .
Mutations of the KRAS gene have been implicated in the development of numerous endometrial malignancies [3] [4] [5] [6] [7] . The mutation in codon 12 of KRAS has been found in 10-30% of endometrial carcinomas. Some studies have indicated that mutations in codon 12 of KRAS are an independent, unfavourable prognostic factor [8] [9] [10] while others have not found this correlation [11] [12] [13] [14] [15] .
A higher prevalence of KRAS mutations in endometrial carcinomas in Japan (30%) compared with other countries (15%) has been indicated [11, 12, 14] . In addition, KRAS mutations have been identified in endometrial hyperplasias (EH) and more frequently in complex atypical hyperplasias (CAH), which suggests the KRAS mutations may be a relatively early event in endometrial carcinogenesis.
In connection with these data, we investigated mutation status of codon 12 of KRAS in surgical specimens of endometrial carcinoma and endometrial hyperplasia using a polymerase chain reaction associated with restriction fragment length polymorphism (PCR-RFPL).
Materials and methods
Tissue samples. 49 patients with histologically confirmed diagnosis of endometrial carcinoma were enrolled into the study (mean age ± SD -62.25 ± 3.75 years). All tumors were staged according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO). Finally, an additional diagnosed set of 11 CAH was included. The initial manifestation of all cases of hyperplasia was an abnormal vaginal bleeding and the age range of patients was 40-52 years. Serial paraffin sections were stained with H+E for light microscopic study. Clinicopathological information was obtained from medical charts and histopathological examination was performed according to the WHO classification. None of the patients had received radiation or hormonal therapy prior to surgery. Only 3 patients were premenopausal and the remaining 46 were postmenopausal.
RFLP.
The detection of KRAS mutations at codon 12 was performed by PCR-RFLP method and the results of the detection were verified by direct sequencing of PCR products. DNA amplification was performed in 20 μl reaction mixture containing 10 -100 ng of genomic DNA isolated from tissue, 1.5 mM of MgCl2, 0.2 μM of dNTPs (Sigma), 0.2 M of each of the primers K1 and DD5P and 1.0 U of Taq DNA polymerase (Sigma) in 1x PCR buffer supplied by the polymerase manufacturer. The K1 upstream primer (5'-ACT GAA TAT AAA CTT GTG GTA GTT GGA CCT -3') was immediately upstream of KRAS codon 12 and introduced a G to C substitution at the first position of the codon 11 of KRAS in order to create a BstOI restriction site (5'-CCT/AGG-3') within the above amplified fragment which overlapped the first two nucleotides of codon 12 and was lost when codon 12 mutations took place. The downstream primer DD5P was as follows: 5'-TCA TGA AAA TGG TCA GAG AA-3'.
Sequencing. After the initial DNA denaturation at 95°C for 3 min, PCR was carried out for 40 cycles (94°C for 15 s, 56°C for 15 s, 72°C for 15 s) followed by terminal extension of PCR products at 72°C for 7 minutes. PCR products were then digested with a restriction endonuclease BstOI. For this purpose, five-microliter aliquots of the post-PCR reaction mixture were digested with 10 U of the restriction endonuclease BstOI (PROMEGA) in the appropriate reaction buffer (supplied by the enzyme manufacturer) in the final volume of 10 μl at 60°C for 3 h. The additional aliquot of 5 U of the enzyme was added to the reaction mixture after the first hour of the digestion. The enzyme recognized the sequence 5'-CCTGG-3', which was present in codon 12 KRAS wild type PCR products, but was absent from the mutant ones. As a result, only the wild type molecules were digested into two fragments -160 bp and 29 bp long. The digestion products were then electrophoresed on a 6% native polyacrylamide gel, stained with ethidium bromide and photographed on a ultraviolet light transilluminator with the use of UVI-KS 400i/Image PC system. The non-restricted PCR products were 189 bp long, whereas the wild type codon 12 products, being restricted inside codon 12 sequence, were 160 bp long. All mutations were then confirmed by direct sequencing of the PCR products. For this purpose, antisense strain of PCR products were sequenced with the antisense primer DD5P, an ABI PRISM BigDye Terminator 
Statistical analysis.
For statistical analysis, the χ 2 test was performed; p<0.05 was considered significant.
Results
The stage of the 49 patients was: Ia -3 cases, Ib -10, Ic -4, IIa -20, IIb -6, IIIa -4, IIIb -1 and IIIc -1 cases. Histologically, 39 of the 49 patients had endometrioid -type carcinoma, 7 had adenocarcinoma with squamous differentiation, 1 had papillary serous carcinoma and 2 had clear cell carcinoma. 28 were welldifferentiated (G 1 ), 14 were moderately differentiated (G 2 ) and 7 were poorly differentiated (G 3 ).
KRAS mutation was detected in 7/39 (14.3%) of tumor specimens and in 2/11 (18.2%) of CAH (Fig. 1) . The results are summarized in Tables 1 and 2 .
Discussion
Although EC is the most common gynecologic cancer in the developed world, the details of its carcinogenesis are still not well known. In the majority of cases, the neoplasm is histologically diagnosed as the endometrioid type (type 1) and its stage at the time of diagnosis is determined as I (FIGO). Some histological properties of EC have a prognostic value as they are associated with the risk of metastases, recurrence and the length of survival. Such prognostic factors include the histological type, grade, depth of myometrium infiltration and lymph-vascular space involvement. Recently, a number of steps in sporadic endometrial carcinogenesis have been identified. The most important basis of understanding molecular events in EC is that this is a hormone-dependent tumor. Additional molecular abnormalities include overexpression of p53 and KRAS point mutations [16, 17] .
RAS oncogenes are the proven proto-oncogenes in human activated by point mutation. The three RAS oncogenes, HRAS, KRAS, and NRAS, share a common amino acid sequence, with a subtle difference in C-terminal part of the polipeptides. The point mutation in codon 12 of RAS oncogene changes glycine to other amino acids except proline, and this transformation results in carcinogenesis.
KRAS point mutations have been implicated in the development of atypical endometrial hyperplasia and EC. These findings suggest that KRAS mutations may be an early oncogenic event in endometrial carcinogenesis [18] . In the case of EC, molecular details are beginning to emerge, which may eventually help advance our understanding of the complex histopathology of this disease. The estrogen-related type 1 EC account for up to 80% of the EC cases and appear to arise via a progression pathway. Frequently, the advanced carcinomas are temporally and spatially associated with complex atypical hyperplasia, which constitutes a range of heterogeneous precancerous lesions. Atypical hyperplasia, the most advanced component of this histopathologic spectrum, is considered to be the direct precursor lesion of type 1 EC. Subsets of type 1 EC were found to contain KRAS mutations (15-20%). Both of these abnormalities were also detected in CAH [19] . Fujimoto et al. reported a 22% KRAS point mutation rate, and this abnormality was associated with high rate in lymph node metastasis [20] . Mizuuchi et al. reported KRAS point mutation as a poor prognostic parameter in EC [9] . Relatively high incidences of KRAS mutations have been reported for EC, especially for type 1 carcinoma, suggesting that mutant KRAS is involved in the development and/or progression of these tumors [8] [9] [10] . In the present study, no correlation was found between KRAS gene mutation and age at onset, histological subtype, grade of differentiation and clinical stage. We conclude that point mutations at codon 12 of KRAS oncogene are a relatively common event in endometrial carcinogenesis, but their prognostic value is limited. 
